List view / Grid view
Increased production of biologic drugs in the global cell line development market is anticipated to bring “significant growth” for mammalian cell line development between 2023-2033, a report shows.
Progress, innovation and sustainability across the pharmaceutical supply chain were recognised at the 2023 CPHI Pharma Awards.
CPHI Barcelona takes place in October 2023, covering a wide range of topics from next generation biomanufacturing and formulation to sustainability.
Following WuXi Biologics’ proposed spin-off of its subsidiary, WuXi XDC has launched new manufacturing facilities that enable doubled capacity antibody intermediates and bioconjugate drug substances.
Lonza’s Associate Director of R&D has offered insight on implementing process analytical technology (PAT) into biologics manufacturing using real-world examples.
WuXi Biologics proposed spin-off and a separate HKEX listing of its subsidiary WuXi XDC means the company will be able to better capture the fast-growing global bioconjugate market.
Improvements in real-time supply chain operations is expected to drive the cell and gene therapy supply chain/logistics market, a report says.
Operation has begun for CRDMO WuXi STA's first continuous manufacturing line for oral solids, in Wuxi city, China.
Private equity overhang to fuel CDMO valuations and expansions, while venture capital overhang will fuel continued demand for services in spite of adverse global conditions.
A University of Cambridge report assessing the preferred relationship type between pharma and contract research organisations (CROs), showed strategic partnerships will continue as the primary collaboration model.
Market research suggests the global formulation development outsourcing market will significantly expand in coming years, owing to disease burden and R&D expenditure.
WuXi Biologics awarded the Bioprocessing Excellence in Viral Clearance and Safety accolade for the second time at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics-300x278.jpg)
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics.jpg)
Global biotechnology company WuXi has demonstrated the success of the CRDMO business model by publishing news of its bumper projects and revenues fuelled by innovative technology platforms in 2021.
Research suggests rising demand for lab automation will help promote the growth of the laboratory information management system (LIMS) market.
Pharma companies outsourcing clinical research support without focusing on safety are paying the price. Here, Natalia Vlcek, Pharmacovigilance Manager and EU QPPV at Arriello Group, offers some practical tips for ensuring best practice when it comes to safety in clinical research outsourcing.
